NCT02908529View on ClinicalTrials.gov

Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2018

Conditions
Obstructive Sleep Apnea (OSA)
Interventions
DRUG

Combination product of Atomoxetine and Oxybutynin

Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep

DRUG

Placebo, 2 tablets

Placebo 2 tablets 2 hours before sleep

Trial Locations (1)

02115

Sleep Disorders Research Program Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT02908529 - Atomoxetine and Oxybutynin in Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter